Kiadis Pharma to present at upcoming conference in August 2019
31 Juillet 2019 - 05:45PM
Kiadis Pharma to present at upcoming conference in August 2019
Kiadis Pharma to present at upcoming
conference in
August 2019
Amsterdam, The Netherlands, July 31,
2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”)
(Euronext Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces it is scheduled to
attend the following conference in August 2019.
Cannacord Genuity 39th Annual Growth
ConferenceAugust 7-8, 2019, Boston, MA
Management will present on August 7th at
09.00-09.25am EDT and will host meetings.
A live webcast of the presentation will be available here:
http://wsw.com/webcast/canaccord35/kds/ An archived replay of the
webcast will be available on the Company's website for
approximately 90 days following the presentation.
Kiadis Contacts:
Kiadis
Pharma:Maryann Cimino, Manager, Corporate AffairsTel. +1
617 710 7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya Mathur, Hollie VileTel:
+44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
About Kiadis PharmaFounded in
1997, Kiadis Pharma, is a fully integrated biopharmaceutical
company committed to developing innovative therapies for patients
with late-stage blood cancers. With headquarters in Amsterdam, the
Netherlands, and offices in the US and across Europe, Kiadis Pharma
is leveraging the natural strengths of humanity and our collective
immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at www.kiadis.com.
Forward Looking
StatementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma’s
or, as appropriate, Kiadis Pharma’s directors’ current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.